UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data

Multiple sclerosis, 2024-05, Vol.30 (6), p.696-706

2024

Volltextzugriff (PDF)

A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis

Human molecular genetics, 2023-03, Vol.32 (6), p.998-1009

2023

Volltextzugriff (PDF)

An integrative study of genetic variants with brain tissue expression identifies viral etiology and potential drug targets of multiple sclerosis

Molecular and cellular neuroscience, 2021-09, Vol.115, p.103656-103656, Article 103656

2021

Volltextzugriff (PDF)

Dense module searching for gene networks associated with multiple sclerosis

BMC medical genomics, 2020-04, Vol.13 (Suppl 5), p.48-12, Article 48

2020

Volltextzugriff (PDF)

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole

Annals of neurology, 2011-04, Vol.69 (4), p.673-680

2011

Volltextzugriff (PDF)

Imaging markers of multiple sclerosis prognosis

Current opinion in neurology, 2017-06, Vol.30 (3), p.231-236

2017

Volltextzugriff (PDF)

Choroid plexus volume differentiates MS from its mimics

Multiple sclerosis, 2024-07, Vol.30 (8), p.1072-1076

2024

Volltextzugriff (PDF)

Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology

Neurology : neuroimmunology & neuroinflammation, 2021-05, Vol.8 (3)

2021

Volltextzugriff (PDF)

Effect of intrinsic and extrinsic factors on global and regional cortical thickness

PloS one, 2014-05, Vol.9 (5), p.e96429

2014

Volltextzugriff (PDF)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

CNS drugs, 2022-12, Vol.36 (12), p.1285-1299

2022

Volltextzugriff (PDF)

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis

Annals of neurology, 2016-05, Vol.79 (5), p.726-738

2016

Volltextzugriff (PDF)

Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias

Movement disorders, 2011-02, Vol.26 (3), p.534-538

2011

Volltextzugriff (PDF)

Brain networks disconnection in early multiple sclerosis cognitive deficits: An anatomofunctional study

Human brain mapping, 2014-09, Vol.35 (9), p.4706-4717

2014

Volltextzugriff (PDF)

Trends in central nervous system-active polypharmacy among people with multiple sclerosis

Multiple sclerosis, 2024-05, p.13524585241251986-13524585241251986

2024

Volltextzugriff (PDF)

Correcting synthetic MRI contrast-weighted images using deep learning

Magnetic resonance imaging, 2024-02, Vol.106, p.43-54

2024

Volltextzugriff (PDF)

Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis

Multiple sclerosis and related disorders, 2019-05, Vol.30, p.69-75

2019

Volltextzugriff (PDF)

The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study

Annals of neurology, 2015-10, Vol.78 (4), p.554-567

2015

Volltextzugriff (PDF)

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Drugs -- real world outcomes, 2021-12, Vol.8 (4), p.497-508

2021

Volltextzugriff (PDF)

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.65-75

2021

Volltextzugriff (PDF)

Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy

NMR in biomedicine, 2018-03, Vol.31 (3), p.n/a

2018

Volltextzugriff (PDF)

Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis

International journal of MS care, 2023-03, Vol.25 (2), p.56-62

2023

Volltextzugriff (PDF)

Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: A retrospective analysis from the CombiRx trial

European journal of neurology, 2022-02, Vol.29 (2), p.515-521

2022

Volltextzugriff (PDF)

Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study

Multiple sclerosis and related disorders, 2023-12, Vol.80, p.105085-105085, Article 105085

2023

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Neurosciences & Neurology
(22)
Humans
(21)
Clinical Neurology
(19)
Multiple Sclerosis
(19)
Neurosciences
(17)
Male
(11)
Adult
(10)
Female
(10)
Magnetic Resonance Imaging
(10)
Middle Aged
(9)
Multiple Sclerosis - Diagnostic Imaging
(6)
Aged
(5)
Disease Progression
(5)
Retrospective Studies
(5)
Young Adult
(5)
Brain - Pathology
(4)
Life Sciences
(4)
Magnetic Resonance Imaging - Methods
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data

A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis

An integrative study of genetic variants with brain tissue expression identifies viral etiology and potential drug targets of multiple sclerosis

Dense module searching for gene networks associated with multiple sclerosis

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS

Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4′-methylaminophenyl)- 6-hydroxybenzothiazole

Imaging markers of multiple sclerosis prognosis

Choroid plexus volume differentiates MS from its mimics

A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis

Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology

Effect of intrinsic and extrinsic factors on global and regional cortical thickness

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis

Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias

Brain networks disconnection in early multiple sclerosis cognitive deficits: An anatomofunctional study

Trends in central nervous system-active polypharmacy among people with multiple sclerosis

Correcting synthetic MRI contrast-weighted images using deep learning

Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis

The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy

Outcomes and Health Care Service Use in Adults 50 Years or Older With and Without Multiple Sclerosis: A 6-Year Observational Analysis

Cerebellar pathology and disability worsening in relapsing‐remitting multiple sclerosis: A retrospective analysis from the CombiRx trial

Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study

Suchergebnisse filtern